Dexfenfluramine influences dietary compliance and eating behaviors of obese subjects.
Results of a 14-month Dutch study using dexfenfluramine as an appetite suppressant show that although weight loss was not enhanced, subjects showed greater dietary compliance and were less anxious about eating behaviors than placebo-treated counterparts. Adjunctive dietary drug therapy may be useful for clinicians working with obese patients in long-term weight loss trials, and may show promise in the treatment of bulimia.
D005247:Feeding Behavior / Q000187:drug effects*; D005277:Fenfluramine / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000178:diet therapy*; D010349:Patient Compliance
D005277:Fenfluramine